TrkB Receptor Antagonists for Cognitive Flexibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective drugs that selectively target and improve cognitive flexibility, a crucial mental function impaired in various conditions such as ADHD, OCD, autism spectrum, and schizophrenia, due to excessive signaling by brain-derived neurotrophic factor (BDNF) via its receptor tyrosine kinase B (TrkB).
Innovation Solution
Administration of a therapeutically effective amount of a selective TrkB receptor antagonist compound, such as ANA-12, cyclotraxin-B, or their derivatives, which inhibit TrkB signaling without affecting TrkA or TrkC, to improve cognitive flexibility by reducing excess BDNF signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If excess BDNF signaling via TrkB is present, then cognitive flexibility is impaired, but no selective drug treatment is available to improve it
Solution Approach 1:
The patent introduces a selective TrkB receptor antagonist as an intermediary substance that mediates between the excess BDNF signaling and the TrkB receptor. This antagonist binds to TrkB with high selectivity, blocking the harmful excess signaling pathway without affecting other neurotransmitter systems, thereby restoring cognitive flexibility in a targeted manner.
Solution Approach 2:
The patent changes the biochemical parameter of TrkB receptor activity by introducing a selective antagonist that specifically modulates TrkB signaling. This parameter change allows for precise control of BDNF-TrkB interactions, reducing excess signaling while preserving necessary physiological functions, thereby improving cognitive flexibility without off-target effects.
2Reliability
If general neurotransmitter modulation is used to treat cognitive impairment, then multiple brain regions are affected, but selective improvement of cognitive flexibility is not achieved
Solution Approach 1:
The patent applies local quality by designing a drug with highly selective affinity for the TrkB receptor subtype. This selectivity ensures that the therapeutic action is localized to specific neural circuits where TrkB mediates cognitive flexibility, rather than broadly affecting all neurotransmitter systems. The selective antagonist concentrates its effect on the relevant pathological pathway while sparing other brain functions.
Solution Approach 2:
The patent segments the neurotrophin receptor family into distinct targets by developing an antagonist that specifically binds to TrkB while not affecting TrkA or TrkC receptors. This segmentation allows for targeted intervention in the BDNF-TrkB signaling pathway that is specifically implicated in cognitive flexibility, separating it from other neurotransmission pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TrkB receptor antagonist compounds demonstrate statistically significant improvement in cognitive flexibility in subjects, as shown in mouse models, with ANA-12 reducing anxiety- and depression-related behaviors and enhancing reversal learning abilities.
Implementation Method 1
excess signaling by brain derived neurotrophic factor (BDNF) via TrkB is associated with impaired cognitive flexibility
Implementation Method 2
The actions of the neurotransmitters dopamine, glutamate and GABA in multiple brain regions including the frontal cortex and basal ganglia are important regulators of cognitive flexibility
Data Source
AI summary
The cognitive flexibility of a subject may be improved by administering a therapeutically effective amount of a TrkB receptor antagonist to the subject in need thereof. The TrkB receptor antagonist compound may be administered in a pharmaceutical dosage form.